Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Project details
Israeli medical company seeks investment.
Project region | Israel |
---|---|
Industry | Healthcare |
Total value of the target | N/A |
Expected target net rate of return after deducting all taxes and fees | N/A |
Validity period of pending order | 365 |
CONTACT ADVISOR
-
Simon Laube
Assistant Manager, International Business Advisory
Project highlights | Ophthalmology medical - CE-certified III drug & clinical evidence - increase compliance |
---|---|
Project description |
The Israeli medical company has a product that is a microemulsion composed of phospholipids and triglycerides. It can form a tear film like elastic lipid shield to improve vision. It is a CE-certified III drug. Project is designated for post-operative ophthalmic surgery (e.g., refractive surgery, cataract surgery, and corneal transplantation), corneal erosion, and dry eye syndrome. This product is the only product on the eye drops market with clinical evidence that corneal epithelium thickens again after mechanical, traumatic, and surgical epithelial loss. As a microemulsion carrier, the technology can be used as a drug delivery platform in the pre-clinical stage. Its unique pharmaceutical advantages include a longer contact time between drug and eye surface which can increase compliance. The company seeks investment. |
Enquire for more information about our services, and how we can help solve challenges for your organization
Contact UsOur Clients
Discover our esteemed global clients across diverse sectors. We believe in providing our clients with exceptional service and a commitment to being their partner for growth in Asia.
See what our clients say about us